Genzyme Corp. (NASDAQ: GENZ) announced that it will build an additional manufacturing plant in Geel, Belgium, to support the long-term growth of Myozyme® and Lumizyme® for Pompe disease. The company held a ceremony in Geel to mark the start of construction of the new €250 million plant,

H. Lundbeck A/S (Lundbeck) announced the advancement of zicronapine into clinical phase III based on the positive clinical phase II data. The first study in the clinical phase III programme is expected to enrol some 160 patients with the aim to measure the efficacy of zicronapine and risperidone and their relative impact on key metabolic parameters.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that BRIM3, a Phase III clinical study of RG7204 (PLX4032), met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma.

Bayer HealthCare and Regeneron Pharmaceuticals announced initiation of a new Phase III clinical trial in collaboration with the Singapore Eye Research Institute (SERI) investigating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution) in patients with choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia.

Amgen Inc. (Nasdaq: AMGN) and Boehringer Ingelheim have signed an agreement under which Boehringer Ingelheim will acquire Amgen's rights in and substantially all assets at Amgen's Fremont California development and manufacturing facility.

GlaxoSmithKline (GSK) announced that it expects to record a legal charge for the fourth quarter of 2010 of £2.2 billion ($3.4 billion) (equating to an after tax cost of £1.8 billion).

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the European Commision has cleared sanofi-aventis' proposed acquisition of Genzyme Corporation unconditionally under EU merger control rules.